Skip to Main Content

The Food and Drug Administration on Friday approved the first drug that benefits patients with lung cancer caused by a specific genetic mutation to a protein called KRAS, a target that for decades was considered to be “undruggable.”

The new medicine, a pill called Lumakras, was developed by Amgen.


Lumakras was cleared to treat patients with advanced non-small cell lung cancer containing a specific type of KRAS alteration called G12C. The mutation, previously untreatable, is found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!